Everbridge (EVBG) PT Raised to $135 at Needham & Company After Analyst Day Reveals Innovative Sales Strategy

Needham & Company analyst Scott Berg raised the price target on Everbridge (NASDAQ: EVBG) to $135.00 (from $115.00) after the company hosted a virtual analyst day that included the company's value proposition given today's COVID-19 driven macro environment. Additionally, the company announced the acquisition of one2many, which could increase EU marketshare.

The analyst reiterated the Buy rating, stating "While the current healthcare crisis is shining a bright spotlight on the company's CEM platform, including three new COVID-19 based templates to help effectively manage the current crisis, we view these templates as a brilliant marketing Trojan Horse to drive incremental CEM deals as COVID-19 concerns lessen".

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Alpha & Omega Semiconductor (AOSL) PT Lowered to $45 at Needham
• Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)